Insys Therapeutics Inc (NASDAQ:INSY) saw unusually large options trading activity on Thursday. Traders purchased 2,156 put options on the company. This is an increase of 1,300% compared to the average daily volume of 154 put options.

Several research firms have weighed in on INSY. Zacks Investment Research raised shares of Insys Therapeutics from a “hold” rating to a “buy” rating and set a $8.50 price target for the company in a research note on Wednesday, October 18th. Royal Bank of Canada set a $8.00 price objective on shares of Insys Therapeutics and gave the company a “buy” rating in a research report on Friday, October 27th. Jefferies Group decreased their price objective on shares of Insys Therapeutics from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, November 3rd. Oppenheimer restated a “hold” rating on shares of Insys Therapeutics in a research report on Sunday, November 12th. Finally, ValuEngine upgraded shares of Insys Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $9.38.

A number of institutional investors have recently modified their holdings of the stock. Janney Montgomery Scott LLC bought a new position in Insys Therapeutics during the third quarter valued at approximately $135,000. Schwab Charles Investment Management Inc. lifted its position in Insys Therapeutics by 31.1% during the third quarter. Schwab Charles Investment Management Inc. now owns 104,812 shares of the specialty pharmaceutical company’s stock valued at $931,000 after purchasing an additional 24,869 shares during the period. Wells Fargo & Company MN lifted its position in Insys Therapeutics by 50.1% during the third quarter. Wells Fargo & Company MN now owns 41,516 shares of the specialty pharmaceutical company’s stock valued at $368,000 after purchasing an additional 13,849 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in Insys Therapeutics during the third quarter valued at approximately $119,000. Finally, Schneider Capital Management Corp increased its holdings in Insys Therapeutics by 100.0% during the second quarter. Schneider Capital Management Corp now owns 119,973 shares of the specialty pharmaceutical company’s stock valued at $1,518,000 after buying an additional 60,000 shares during the last quarter. Institutional investors own 25.35% of the company’s stock.

Shares of Insys Therapeutics (INSY) traded up $0.38 on Monday, reaching $10.13. 936,473 shares of the company’s stock were exchanged, compared to its average volume of 3,082,350. The stock has a market capitalization of $737.57, a PE ratio of -3.97 and a beta of 0.76. Insys Therapeutics has a twelve month low of $4.10 and a twelve month high of $15.02.

Insys Therapeutics (NASDAQ:INSY) last issued its earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.02). Insys Therapeutics had a negative return on equity of 11.76% and a negative net margin of 112.56%. equities research analysts anticipate that Insys Therapeutics will post -0.63 earnings per share for the current fiscal year.

WARNING: This piece of content was reported by Marea Informative and is owned by of Marea Informative. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.mareainformativa.com/investors-purchase-large-volume-of-put-options-on-insys-therapeutics-insy-updated-updated-updated/125336/.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.